Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
tRNA-derived fragments: biomarkers and therapeutic targets in autoimmune diseases
Publication Year: 2025 Source: Immunol Res PMID: 40402330 DOI: 10.1007/s12026-025-09639-0
TRNA-derived fragments (tRFs) are tiny non-coding RNAs that control gene expression and immunological responses. Initially, the tRFs were thought to be only a byproduct of Transfer RNA (tRNA) degradation. Recent studies highlighted their role in autoimmune diseases like type 1 diabetes (T1D), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), sjogren's …
From Surgery to Strength: The Case for Mental Health Integration in Ileostomy Care
Publication Year: 2025 Source: Dig Dis Sci PMID: 40402428 DOI: 10.1007/s10620-025-09054-3
Ileostomy, a surgical intervention required for conditions such as inflammatory bowel disease (IBD), colorectal cancer, trauma, and sepsis, can be a transformative intervention and imposes substantial physical and psychological challenges on patients. While the physical aspects of ileostomy care are well addressed, the psychological burden-marked by anxiety, depression, and diminished …
From bench to bedside: the clinical landscape of microbiome modulator therapy for inflammatory bowel disease
Publication Year: 2025 Source: Int J Surg PMID: 40402641
No Abstract
PUS10-induced tRNA fragmentation impacts retrotransposon-driven inflammation
Publication Year: 2025 Source: Cell Rep PMID: 40402745
Pseudouridine synthases (PUSs) catalyze the isomerization of uridine (U)-to-pseudouridine (Psi) and have emerging roles in development and disease. How PUSs adapt gene expression under stress remains mostly unexplored. We identify an unconventional role for the Psi "writer" PUS10 impacting intracellular innate immunity. Using Pus10 knockout mice, we uncover cell-intrinsic upregulation …
Startups and the next frontier of inflammatory bowel disease therapy: a guide for the brave
Publication Year: 2025 Source: Curr Opin Gastroenterol PMID: 40402837 DOI: 10.1097/MOG.0000000000001100
PURPOSE OF REVIEW: This review explores the evolving landscape of inflammatory bowel disease (IBD) therapy, particularly through the lens of startups that are pushing the boundaries of current treatment paradigms. By discussing the challenges and opportunities faced by startups, this review seeks to provide insights for aspiring entrepreneurs and innovators …
Key updates in Crohn's disease surgery for the gastroenterologist in 2025
Publication Year: 2025 Source: Curr Opin Gastroenterol PMID: 40402838 DOI: 10.1097/MOG.0000000000001102
PURPOSE OF REVIEW: The field of inflammatory bowel disease (IBD) has been evolving at an unprecedented rate. Not only does this apply to the medical management of IBD but also to its surgical management. This review aims to highlight the major updates in the current surgical approach in Crohn's disease. …
Safety and immunogenicity of the measles-mumps-rubella vaccine in immunocompromised children with inflammatory bowel disease, or after liver transplantation: An observational study
Publication Year: 2025 Source: Vaccine PMID: 40403417
Safety of live vaccines is questioned in children with inflammatory bowel diseases and after liver transplantation receiving immunosuppressive therapy. The objective was to monitor the immunogenicity and safety of attenuated live vaccines against measles, mumps and rubella (MMR) in children receiving immunosuppressive therapy. In this prospective multicenter observational study (DRKS00014569) …
Repurposing of clinical-stage FLT3 inhibitor HYML-122 as a potent RIPK2 inhibitor for the treatment of inflammatory bowel disease
Publication Year: 2025 Source: Int Immunopharmacol PMID: 40403506 DOI: 10.1016/j.intimp.2025.114839
Nucleotide-binding oligomerization domain-containing proteins 1 and 2 (NOD 1/2) are important cytoplasmic pattern recognition receptors that initiate host immune responses. Dysregulation of NOD signaling is highly associated with inflammatory bowel disease (IBD) and necessitate efficient treatment options. As a key mediator of NOD signals, receptor-interacting protein kinase 2 (RIPK2) was …
Computer-driven formulation development of dipyridamole dry nanosuspension
Publication Year: 2025 Source: Int J Pharm PMID: 40403995 DOI: 10.1016/j.ijpharm.2025.125739
Dipyridamole (DIP) has shown promising effectiveness in treating Inflammatory Bowel Disease (IBD), especially in pediatric populations. However, existing formulations are unsuitable for children due to poor solubility and swallowing difficulties. This research aims to develop a novel DIP formulation with improved dissolution rate and bioavailability, tailored for children, using computational …
Corrigendum to "Immune modulation for the patterns of epithelial cell death in inflammatory bowel disease" [Int. Immunopharmacol. 154 (2025) 114462]
Publication Year: 2025 Source: Int Immunopharmacol PMID: 40404517
No Abstract
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide